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2021;111:314-26 SHV CHARACTERISTICS FOR OPTIMAL VALVE SELECTIONComprehensive information on the characteristics of
surgical heart valves (SHVs) is essential for optimal valve
selection. Such information is also important in assessing
SHV function after valve replacement. Despite the
existing regulatory framework for SHV sizing and
labelling, this information is challenging to obtain in a
uniform manner for various SHVs. To ensure that clini-
cians are adequately informed, the European Association
for Cardio-Thoracic Surgery (EACTS), The Society of
Thoracic Surgeons (STS) and American Association for
Thoracic Surgery (AATS) set up a Task Force comprised
of cardiac surgeons, cardiologists, engineers, regulatory
bodies, representatives of the International Organiza-
tion for Standardization and major valve manufac-
turers. Previously, the EACTS–STS–AATS Valve
Labelling Task Force identified the most importantproblems around SHV sizing and labelling. This Expert
Consensus Document formulates recommendations for
providing SHV physical dimensions, intended implant
position and hemodynamic performance in a trans-
parent, uniform manner. Furthermore, the Task Force
advocates for the introduction and use of a standard-
ized chart to assess the probability of prosthesis–
patient mismatch and calls valve manufacturers to
provide essential information required for SHV choice
on standardized Valve Charts, uniformly for all SHV
models.
(Ann Thorac Surg 2021;111:314-26)
 2021 Jointly between The Society of Thoracic Surgeons,
the American Association for Thoracic Surgery, and the
European Association for Cardio-Thoracic SurgeryIntroduction






Cacteristics of surgical heart valves (SHVs) is essential
for optimal valve selection. This information is also
important in assessing SHV function after valve replace-
ment. Despite the existing regulatory framework1,2 and the
efforts by the International Organization for Standardiza-
tion (ISO),3 the amount and quality of currently available
information on SHV characteristics provided by manu-
facturers is not optimal and often not uniform, rendering
intraoperative SHV selection challenging.
To ensure that clinicians are provided with the
necessary information, the European Association for
Cardio-Thoracic Surgery (EACTS), The Society of
Thoracic Surgeons (STS) and American Association for
Thoracic Surgery (AATS) established the EACTS–STS–
AATS Valve Labelling Task Force, composed of cardiac
surgeons, cardiologists, engineers, regulatory pro-
fessionals and representatives of major valve
manufacturing companies.
The first document of the Task Force addressed the
following issues around SHV sizing and labelling: (i)
non-uniform or incomplete reporting of SHV materials
and physical dimensions; (ii) non-uniform marking of
SHV support structures (e.g. sewing rings); (iii) unclear
definition of labeled valve size and inconsistencies be-
tween sizer dimensions and labeled valve size; (iv) lack
of robust information to reliably predict SHV hemody-
namic performance; (v) lack of uniform tools to predict
and prevent prosthesis–patient mismatch (PPM); and
(vi) lack of good-quality, robust clinical data on SHV
thrombogenicity.4
This second Expert Consensus Document of the Task
Force provides recommendations on the information that
should be provided together with an SHV, to ensure
consistent comparability of different SHVs and to facili-
tate optimal intraoperative SHV selection.Physical Dimensions of Surgical Heart Valves
Defining uniform, standardized physical dimensions is
necessary to objectively compare various SHVs. CurrentISO standards for cardiac valves provide definitions
only for ‘internal orifice diameter’, ‘profile height’ and
‘outflow tract profile height’,3 and manufacturers often
use non-uniform terminology to describe the physical
dimensions of their SHVs. Furthermore, it is not always
easy to find detailed information on the physical di-
mensions of an SHV.5
The Task Force recommends that manufacturers pro-
vide the physical dimensions of SHVs using the termi-
nology listed in Tables 1 and 2. Physical dimensions
should be provided in millimetres, with preferably at
least 1 decimal place precision. In addition, a pictogram of
the SHV should be presented, clearly indicating the cor-
responding physical dimensions. Example tables and
pictograms for standardized displaying of the physical
dimensions of stented biological and mechanical SHVs in
the aortic and mitral position are provided in Figures 1
and 2.
Although defined in the ISO 5840 standard,3 ‘internal
orifice diameter’ (the minimum diameter within an SHV
through which blood flows) is difficult to determine for
certain bioprosthetic SHVs6 and some manufacturers
have refrained from reporting it. In specific bioprosthetic
SHV designs, the orifice available for flow is encircled by
the prosthetic leaflets and it is smaller than the internal
stent diameter (Figure 2A). Furthermore, the uneven
surface created by the leaflets makes exact measurements
difficult. Considering the inconsistency in the use and
reporting of ‘internal orifice diameter’, the Task Force
advocates the use of ‘minimum internal diameter’ to
define the smallest diameter theoretically available for
flow within an SHV orifice.
The minimum internal diameter of a bioprosthesis, also
termed as ‘true internal diameter (true ID)’, is important
when a valve-in-valve procedure is planned.6 Some have
tried to determine this dimension of bioprosthetic SHVs
by manually passing a circular sizing tool through the
orifice of the SHV in 0.5mm increments.6 However, these
results might not be always accurate since the force used
for passing the sizers through the orifice is not stan-
dardized. A standardized method for determining ‘min-
imum internal diameter’ during bench testing should be




Overall profile height Maximal axial dimension of an SHV in the open or closed position,
whichever is greater
A 3
Outflow profile height Maximum distance that the SHV extends axially into the outflow tract in the
open or closed position, whichever is greater, measured from the valve
structure intended to mate with the top (atrial or aortic/pulmonic side) of
the patient’s annulus
B 3
Minimum internal diametera The smallest diameter within an SHV orifice, which is theoretically available
for flow
C 3
External housing diameter The largest external diameter of the supporting frame (housing) D b
External sewing ring
diameter
The largest diameter of the uncompressed sewing ring E b
aDefined in the ISO 5840:2015 as ‘internal orifice diameter’; bNot defined in the ISO 5840:2015.
ISO, International Organization for Standardization; SHV, surgical heart valve.
316 PRACTICE GUIDELINE DURKO ET AL Ann Thorac Surg







developed, and this dimension should be made available
by the manufacturers, for all bioprosthetic SHV models
and sizes, along with the other physical dimensions of the
prosthesis. It is important that these determinations of
this dimension are calculated in a similar standardized
manner across all manufacturers with accepted protocols
with reproducibility amongst laboratories.Position of Surgical Heart Valves Relative to the
Annulus
The intended position of an SHV related to the patient
tissue annulus has important implications on the surgical
technique and more importantly on the hemodynamic
performance of the SHV following implantation.7,8 Man-
ufacturers should provide clear guidance regarding the
intended implant position of an SHV. Currently, the ter-
minology and definitions provided by the ISO 5840:2015
standard (Table 3) are used for this purpose.3 However,
this terminology has certain shortcomings since it isTable 2. Physical Dimensions of Bioprosthetic SHVs
Physical Dimension Defi
Overall profile height Maximal axial dimension of an SHV
whichever is greater
Outflow profile height Maximum distance that the SHV exte
open or closed position, whichever
structure intended to mate with th
the patient’s annulus
Minimum internal diametera The smallest diameter within an SHV
for flow
Internal stent diameterb The smallest internal diameter of the
covering
External stent diameterb The largest external diameter of the
External sewing ring
diameterb
The largest diameter of the uncompr
aDefined in the ISO 5840:2015 as ‘internal orifice diameter; bNot applicable
ISO, International Organization for Standardization; SHV, surgical heart valveunclear how certain aortic SHVs, primarily seated above
but with partial extension into the annulus, should be
classified.4
An easy way to overcome the ambiguity of the current
‘supra-annular’ and ‘intra-annular’ terminology is that
manufacturers provide a standardized pictogram, clearly
indicating the intended position(s) of the SHV after im-
plantation, related to the tissue annulus of the patient.
Example pictograms indicating the position of an aortic
SHV related to the annulus are provided in Figure 3 for
aortic and in Figure 4 for mitral mechanical and bio-
prosthetic valves.Labeled Valve Size and Intraoperative Sizing
The proper interpretation of ‘labeled valve size’ is one of the
most challenging issues around SHV labelling, causing the
most confusion in the surgical community.9 Labeled valve
size is defined as the ‘tissue annulus diameter of the patient
into which the SHV is intended to be implanted’ in the ISOnition
Label on
Figure 2 Reference
in the open or closed position, A 3
nds axially into the outflow tract in the
is greater, measured from the valve
e top (atrial or aortic/pulmonic side) of
B 3
orifice, which is theoretically available C 3
supporting frame (stent), without fabric D c
stent, with fabric covering E c
essed sewing ring F c
for stentless bioprosthetic SHVs; cNot defined in the ISO 5840:2015.
.
Figure 1. Standardized
approach to present surgical
heart valve physical di-
mensions: mechanical valves
in the (A) aortic and (B) mitral
position. The Task Force sug-
gests that manufacturers use a
complete, standardized set of
physical dimensions and a
standardized pictogram when
describing their surgical heart
valves.
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5840:2015 standard.3 In other words, labeled valve size re-
flects the manufacturer’s recommendation into which
annulus an SHV can be safely implanted. To emphasize that
the actual meaning of ‘labeled valve size’ is ‘patient tissue
annulus diameter’, manufacturers should always present
‘labeled valve size’ as a separate variable when presenting
the physical dimensions of SHVs. Surgeons should simi-
larly realize that the corresponding valve size is simply a
label, and not a true measure of the valve size.
It is not possible to design valves for each annulus size.
Therefore, labeled valve sizes are practically representing
tissue annulus diameter ranges, where a specific SHV is
recommended to be implanted according to the manu-
facturer.10,11 These ranges are defined by the valve-
related tubular sizers. The lower margin of this range is
the diameter of the largest valve-related tubular sizer that
fits the annulus. The upper margin of this range is indi-
rectly bordered by the diameter of the sizer 1 size larger
(the sizer that does not fit).
It is sensible that the actual (numerical) labeled size of
an SHV falls within these margins (Figure 5).12 However,
as the margins of these tissue annulus ranges were not
defined in the corresponding ISO standards,3 they can
vary for different SHV models having the same labeled
valve size (Figure 6). This historical lack of standardiza-
tion renders the direct comparison of different SHVs
based on labeled valve size impossible, precludes the
exclusive use of a universal sizing tool, limits standard
sizing and ultimately causes confusion in the surgical
community.13
Redefining these ‘tissue annulus ranges’ belonging to
specific labeled sizes would demand major changes in
existing SHV designs. For transparency, however, it is
necessary to disclose the margins of these ‘tissue annulus
ranges’. This can easily be accomplished by disclosing the
actual diameters of the tubular ends of the valve-related
sizers and would clarify into which patients a specific
SHV is ‘intended to be implanted’.
Besides sizing with the cylindrical end of the valve-
related sizer, the replica end of the sizer helps todetermine the final fit and position of the SHV. Of note,
the size of the replica can slightly differ from the actual
dimensions of the corresponding SHV. This is due to the
different properties of the sizer and SHV materials
(mainly different flexibility, with a stiff sizer correspond-
ing to a flexible SHV), and this should be considered
during intraoperative sizing.Providing Information on Predicted Hemodynamic
Performance
Accurate and reliable information regarding the hemo-
dynamic performance of an SHV after implantation is an
important factor in optimal SHV choice. Also, comparison
of measured and reference transprosthetic gradients and
effective orifice area (EOA) values are used to assess SHV
function during follow-up.14
Information on SHV hemodynamic performance can
be obtained by benchtop in vitro measurements, by
in vivo large animal studies and by using in vivo data
from reference patient populations. Benchtop mock cir-
culatory loops used for in vitro testing and animal models
are not perfect substitutes of the human circulation, and
results can be influenced by differences in experimental
protocols.15,16 Hence, in vitro hydrodynamic data or data
from animal experiments should not be used to characterize
or predict hemodynamic performance of SHVs in a clinical
setting. In vivo data, derived from Doppler echocardiogra-
phy measurements, performed in a reference patient pop-
ulation, should be the primary source to predict the
hemodynamic performance of an SHV after implantation.4,17
Transprosthetic gradients and EOA do not solely
depend on the physical features of an SHV. Doppler
echocardiography measurements are influenced by the
anatomy (upstream and downstream of the prosthesis)
and the physiological state (heart rate, myocardial func-
tion or cardiac output) of the individual patient receiving
an SHV implant. Furthermore, surgical implantation
technique and the timing between surgery and echocar-
diography18,19 can also potentially affect Doppler
Figure 2. Standardized approach to present
surgical heart valve physical dimensions:
bioprosthetic valves in the (A) aortic and
(B) mitral position.
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parameters,8 introducing variability into the results.
In vivo EOA reference values follow a normal distribution
(Figure 7)20 and should always be described with a mean
value and its standard deviation (SD). Theoretically, the
variability (described by the SD of the mean) can be
reduced by increasing the number of patients, standard-
izing Doppler echocardiography protocols and perform-
ing measurements in independent reference laboratories
(core laboratories).Table 3. Current Terminology Used to Describe Annular Attachm
Term to Describe Sewing Ring Configuration De
Intra-annular sewing ring Sewing ring desig
tissue annulus
Supra-annular sewing ring Sewing ring desig
ISO, International Organization for Standardization; SHV, surgical heart valveTo characterize the hemodynamic performance of a
specific SHV model, ‘mean transprosthetic gradients’
and ‘EOAs’ determined by Doppler echocardiography
should be used. Echocardiography used to determine
normal reference values should be performed between
30days and 1 year after implantation and in a minimum
of 30 patients for each labeled size. Data should be
presented as mean  SD for each SHV model and
labeled size, along with source study details [e.g. studyent of SHVs, According to the ISO 5840:2015 Standard
finition Provided in the ISO 5840:2015 Standard3
ned to secure the SHV ‘wholly or mostly’ within the patient’s
ned to secure the valve ‘wholly’ above the patient’s tissue annulus
.
Figure 3. Example of standardized pictograms indicating the
intended implant positions of (A) mechanical and (B) bioprosthetic
surgical heart valves (SHV) in the aortic position. Considering the
ambiguity of the current terminology used to describe the annular
position of SHVs, the Task Force suggests that manufacturers use
standardized pictograms to indicate the ‘intended position(s)’ of their
SHVs related to the tissue annulus of the patient.
Figure 5. Ideal situation: well-defined, uniform relationship
between labeled sizes and tissue annulus ranges. Comparing different
surgical heart valve (SHV) models starts with selecting the valves that
can be fitted into the same tissue annulus. A well-defined, uniform
relationship between ‘labeled valve size’ and the ‘tissue annulus
range’ where an SHV fits would allow direct comparison of SHVs
based on labeled valve size.
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SD age, mean  SD body mass index (BMI) and mean
 SD body surface area (BSA) of patients, per labeled
size], indicating whether the measurements were per-
formed in an independent core laboratory or not.
Whenever possible, only core laboratory adjudicated
data should be used.R
Predicting the Probability of Prosthesis–Patient
Mismatch After Aortic Valve Replacement
PPM is manifested by high transprosthetic gradients
through an otherwise normally functioning SHV. PPMFigure 4. Example of standardized pictograms indicating the
intended implant positions of (A) mechanical and (B) bioprosthetic
surgical heart valves in the mitral position. Knowing the intended
implant position of mitral surgical heart valves is important as these
valves can potentially interfere with the mitral subvalvular appa-






results from the orifice of the implanted SHV being too
small to fulfil the patient’s cardiac output requirements.21
The size of the SHV orifice relative to the patient is
characterized by the ‘indexed EOA’, which is calculated










BSA of the patient ðm2Þ:
PPM is associated with a higher risk of poor outcomes
after aortic valve replacement,22,23 and its prevention is of
paramount importance when selecting an SHV for im-
plantation.24 Cut-off levels of indexed EOA have been
introduced to define moderate and severe PPM after
aortic valve replacement.14
To predict PPM after SHV implantation, valve manu-
facturers provide ‘indexed EOA charts’. The main prin-
ciple of these charts is that by using a ‘reference EOA’ and
the BSA of the patient, the ‘expected indexed EOA’ after
implantation can be calculated and compared to the pre-











BSA of the patient ðm2Þ:
Theoretically, this would make the selection of a large
enough SHV, and thereby the prevention of PPM,
possible. In ‘indexed EOA charts’ provided by valve
manufacturers, expected indexed EOA values are typi-
cally color-coded as follows: ‘green—above PPM cut-off
level’, ‘yellow—moderate PPM’ and ‘red—severe PPM’.
However, PPM charts provided by valve manufacturersFigure 6. Actual situation: the margins of ‘tissue annulus ranges’
belonging to specific labeled valve sizes are not defined. The margins
of ‘tissue annulus ranges’ are not standardized and can be different
for similarly labeled surgical heart valve models. This lack of stan-
dardization precludes direct comparability based on labeled valve size
and the use of a universal sizing tool.
Figure 7. Distribution of the ‘reference EOA’ of a 23-mm
bioprosthetic valve. In vivo reference EOAs of surgical heart valves
(SHVs) are determined in reference patient populations and are
influenced not only by SHV characteristics but also by patient
anatomy and physiology. Reference EOAs have a normal
distribution, described by a mean EOA and its SD. (EOA, effective
orifice area.) (Reproduced from20 with permission from BMJ
Publishing Group Ltd.)
Figure 8. Applying PPM cut-off to the ‘expected indexed EOA’
distribution, to calculate PPM probability. Applying a PPM cut-off
value to the ‘expected indexed EOA’ distribution helps assessing the
‘percentage probability’ of PPM after surgical heart valve
implantation. This method can provide a better understanding of the
actual PPM risk and avoid the shortcomings of classifying predicted
PPM into a ‘yes/no’, binary variable. (iEOA, indexed effective orifice
area; PPM, prosthesis–patient mismatch.)
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have been severely criticized for their inaccuracy.25 Due
to the lack of standardization, the use of different PPM
cut-offs and the questionable quality of their reference
EOAs, these charts are regarded by many as marketing
tools rather than useful clinical assets.26
Standardized PPM charts, however, would (i) help sur-
geons in objectively assessing the probability of PPM
before SHV implantation; (ii) facilitate optimal SHV choice;
and (iii) prevent biased comparisons between different
SHVs.26 Therefore, the Task Force proposes that manu-
facturers provide standardized charts for their aortic SHVs
to predict the probability of severe PPM after implantation.
To create a ‘standardized PPM chart’, the following is
required: (i) high-quality reference EOA values for all
SHV models and sizes from a reliable source; (ii) the use
of uniform PPM cut-off levels; and (iii) a tool to accurately
predict the probability of PPM after SHV implantation.
The use of reliable, high-quality reference EOA values
is of paramount importance. In PPM charts, reference
EOA values derived from large prospective multicentre
clinical studies with standardized core laboratory echo-
cardiography assessment should be used, if possible.
Data from at least 30 patients should be available to
determine the mean  SD reference EOA, for each SHV
model and labeled size. In addition, the following study
details should be provided on the standardized PPM
chart: sample size per labeled SHV size, study charac-
teristics (prospective or retrospective, period of patient
inclusion, single or multicentre, regulatory study or not)
and whether echocardiography was assessed in a core
laboratory.The use of uniform indexed EOA cut-offs is mandatory
to define PPM after aortic valve replacement. Recent
guidelines advocate adjusting PPM cut-offs for the BMI of
the patient.14 In the standardized charts, the following
PPM cut-off values should be used: for non-obese (BMI
<30 kg/m2) patients, severe PPM should be defined as an
indexed EOA of ˂0.65 cm2/m2; while for patients with BMI
30 kg/m2, severe PPM should be defined as an indexed
EOA of 0.55 cm2/m2.14
Instead of classifying PPM simply into a ‘yes/no’ (bi-
nary) variable, knowing the exact probability of severe
PPM is more useful in clinical decision-making. The
standardized PPM chart should therefore provide the
‘probability of severe PPM’ for a given patient in per-
centages, based on the reference EOA of the corre-
sponding SHV (described as mean  SD) and on the BMI
and BSA of the patient.
Expected indexed EOAs are derived from reference
EOAs. Hence, expected indexed EOA values follow the
same distribution as reference EOA values. When
applying the above-mentioned severe PPM cut-offs to
this distribution, the exact probability of PPM can be
calculated (Figure 8). Dividing the area under the curve
below the PPM limit by the area under the curve of the
whole ‘expected indexed EOA distribution’ gives us the
probability of severe PPM:
PPM probability ¼
AUC ’below PPM limit’
AUC ’expected indexed EOA distribution’
:
In standardized PPM charts, the probability of PPM
should be provided using this method. PPM probability
Figure 9. Standardized PPM chart for surgical heart valves in the aortic position. Standardized PPM charts provide the percentage probability of
severe PPM after implantation of an aortic surgical heart valve into a specific patient. Different cut-offs of severe PPM are used for non-obese
(BMI) and obese (BMI) patients. The probability of severe PPM is calculated using the distribution of ‘reference EOAs’, ‘patient BSA’ and the ‘BMI-
adjusted severe PPM cut-off’. The yellow color indicates that the ‘mean expected indexed EOA’ is under the PPM cut-off (percentage probability is
larger than 50%). (BMI, body mass index; BSA, body surface area; EOA, effective orifice area; iEOA, indexed effective orifice area; PPM,
prosthesis–patient mismatch.)
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Figure 10. Standardized Valve Chart: aortic valves. Standardized Valve Charts provide essential information on surgical heart valve (SHV)
characteristics in a uniform manner and allow for comparability between different SHV models without demanding radical changes in current SHV
designs or labelling. Furthermore, Valve Charts highlight the necessity of considering multiple factors when selecting an SHV for implantation.
(BMI, body mass index; BSA, body surface area; EOA, effective orifice area; iEOA, indexed effective orifice area; PPM, prosthesis–patient
mismatch.)
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should be provided in percentages, for BSA ranges be-
tween 1.3 and 2.6m2, in 0.1m2 increments.27
To emphasize that PPM after aortic valve replace-
ment is not only dependent on the characteristics of the
SHV or on the BMI and BSA of the patient, the stan-
dardized PPM chart should contain the following
disclaimer: ‘This chart is a support tool to estimate the
probability of PPM in patients undergoing aortic valve
replacement with a particular prosthetic heart valve,
but the actual risk further depends on specific patient
characteristics and operative technique’. An example of
the proposed standardized PPM chart is provided in
Figure 9.Providing Information for an Optimal Surgical
Heart Valve Choice
To facilitate SHV choice, the Task Force identified the
following essential information regarding SHV charac-
teristics that should be made easily available by valvemanufacturers, for all SHV models and sizes: (i) SHV
‘physical dimensions’, presented in a complete and
standardized way; (ii) ‘tissue annulus ranges’ in which
SHVs can be implanted, characterized by the diameters of
the valve-related tubular sizers; (iii) a standardized
‘pictogram indicating the intended position of the SHV’
after implantation, related to the patient tissue annulus;
(iv) ‘high-quality reference EOA values’; and (v) for aortic
SHVs, a ‘standardized chart to display the probability of
severe PPM’, based on high-quality in vivo reference
EOAs, using standardized, BMI-adjusted PPM cut-offs,
for realistic patient BSA ranges.
Although final SHV choice is typically made in the
operating theatre, surgeons should be provided with all
necessary information required for optimal SHV choice
well before the operation. Currently, medical literature,
marketing materials provided by valve manufacturers,
package labels and instructions for use booklets are the
primary sources of information regarding SHV charac-
teristics.4 The main purpose of package labels is to
Figure 11. Standardized Valve Chart: mitral valves. Information on in vivo hemodynamic performance, physical dimensions, intended implant
position and sizer dimensions should be made available for surgical heart valves in the mitral position. (EOA, effective orifice area.)
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allow easy identification of the product for the end-
user, and throughout the whole supply chain. Further-
more, labels must contain essential information
regarding sterility, manufacturing and the intended use
of the product. However, it is not possible to provide all
information regarding SHV characteristics required for
valve selection on package labels. On the other hand,
instructions for use booklets are typically only acces-
sible after opening the packaging of the SHV and, from
a practical standpoint, it is not possible to study these
booklets in detail in the time-pressured environment of
an operating theatre, during intraoperative SHV
implantation.
Therefore, instead of changing existing package labels,
the Task Force suggests the introduction and the use of a
standardized Valve Chart, to provide comprehensive in-
formation regarding SHV characteristics. Standardized
Valve Charts should be provided by manufacturers and
should contain the following information: (i) manufacturer
name and type of the SHV; (ii) standardized table and
pictogram to present SHV physical dimensions; (iii) sizer
dimensions to indicate the tissue annulus ranges where the
SHVs can be fitted; (iv) standardized pictogram indicating
the intended implant position of the SHV; and (v)standardized PPM chart to predict the probability of PPM,
for SHVs used in the aortic position (vi) issue date and
version number. Valve Charts should have a standardized,
uniform layout. Furthermore, to ensure easy access, Valve
Charts should be made available online on a designated
website endorsed by EACTS, STS and AATS, and in a
smartphone application. Valve Charts should be regularly
revised and updated if new evidence becomes available.
An example of standardized Valve Chart is provided in
Figure 10 for aortic valves and in Figure 11 for mitral SHVs.Selection and Comparison of Surgical Heart Valves
Using the Valve Chart
Valve Charts can be used preoperatively, intraoperatively
or postoperatively, when comparing different SHVs,
when selecting SHVs for implantation or when assessing
SHV function. Possible uses of the Valve Charts in
various clinical scenarios are summarized in Figure 12.
Discussion
Easy access to comprehensive information regarding SHV
characteristics is required for an optimal SHV choice: in
Figure 12. Comparison and selection of SHVs using the Valve Chart. Valve Charts can be used in various settings: when comparing SHVs from
different manufacturers (A) preoperatively or (B) when selecting SHVs for implantation. (BMI, body mass index; BSA, body surface area; EOA,
effective orifice area; PPM, prosthesis–patient mismatch; SHV, surgical heart valve.)
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addition to determining which SHV would fit into the
patient and knowing the intended annular position of the
prosthesis, knowledge of the predicted hemodynamic
performance of the SHV and the probability of PPM after
implantation are matters of the uttermost importance.
On the standardized Valve Charts, this information
could be provided for all SHV models in a uniform
manner, without demanding radical changes in current
SHV designs or labelling. As most of the required infor-
mation is readily available, it should be possible to create
these Charts relatively quickly and easily. Standardized
Valve Charts highlight the necessity of considering mul-
tiple factors when selecting an SHV for implantation. The
ability to consult such charts during the preoperative,
intraoperative and postoperative periods makes objective
comparison of different SHVs and optimal SHV selection
possible, and it helps in the proper assessment of SHV
function during patient follow-up.
Besides the information provided on the Valve Chart,
individual patient characteristics, comorbidities, life ex-
pectancy and preference, local resources and expertise
and predicted in vivo prosthesis durability and throm-
bogenicity should be considered when selecting an SHV
for implantation. Due to the suboptimal quality and
quantity of the currently available data on in vivo SHVdurability and thrombogenicity and considering the sig-
nificant heterogeneity of the definitions used to describe
these important clinical end points,28-30 data regarding
SHV durability and thrombogenicity are not provided on
the Valve Charts.
Problems around SHV sizing and labelling can only be
solved by the cooperation and joint effort of all stake-
holders. The EACTS–STS–AATS Valve Labelling Project
was set up with this intention. This Consensus Document
can serve as a guide for regulatory bodies, when devel-
oping future standards or when refining the framework of
surgical heart valve labelling. In the future, continuous
dialogue and close collaboration of clinicians (repre-
sented by professional societies), engineers, regulatory
bodies, the ISO Cardiac Valves Working Group and valve
manufacturers are mandated to ensure that clinicians are
provided with the necessary information regarding SHV
characteristics all times.Conclusions
This joint EACTS–STS–AATS Valve Labelling Task Force
suggests the use of standardized Valve Charts to present
essential information on SHV characteristics. Valve
Charts should present information on the physical
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dimensions, implant position and hemodynamic perfor-
mance of an SHV in a uniform, standardized manner. For
valves used in the aortic position, Valve Charts should
include a standardized PPM chart to assess the proba-
bility of PPM after implantation.
Continuous dialogue and collaboration of clinicians,
engineers, regulatory bodies, the ISO Cardiac Valves
Working Group and valve manufacturers are essential to
ensure that clinicians are provided with the necessary
information regarding SHV characteristics.
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